

Product Pipeline

	Phase I	Phase II	Phase III	Registration	Approval
<u>Neratinib: Tyrosine kinase inhibitor</u>					
HER2+ Breast Cancer					
Extended adjuvant <i>Neratinib monotherapy</i>			ExteNET (Phase III HER2+ EBC*)		
Metastatic <i>Monotherapy or combo therapy</i>			NALA (Phase III 3 rd Line HER2+ MBC**)		
Metastatic w/ brain mets <i>Monotherapy or combo therapy</i>			TBCRC-022 (T-DM1 + neratinib)		
HER2-mutant Solid Tumors			SUMMIT		
<u>Alisertib: Aurora kinase A inhibitor</u>					
HRc+*** HER2-negative MBC			TBCRC-041 (fulvestrant + alisertib)		
			NCT02187991 (paclitaxel + alisertib)		
Triple-negative MBC			NCT02187991 (paclitaxel + alisertib)		
Small cell lung cancer			NCT02038647 (paclitaxel + alisertib)		

*

